| 期刊全称 | Adjuvant Therapy of Breast Cancer V | | 影响因子2023 | Hans Jörg Senn,Richard D. Gelber,Beat Thürlimann | | 视频video | | | 学科分类 | Recent Results in Cancer Research | | 图书封面 |  | | 影响因子 | We often hear physicians, health care professionals, poli ticians, and patient advocates that "nothing has happened in the treatment of breast cancer," since patients with breast cancer, the most frequent neoplastic condition in women in industrialized countries, are continuing to suffer relapse and succumb to this dreadful disease! This negativistic attitude does not seem to be justified, but, why is the transmission of clinical trial results into general practice, and with it progress, such a slow process? After many decades of frustrating stagnation of long-term survival expectations, in all stages of early, oper/lble breast cancer treated only by surgery and locoregional radio therapy, adjuvant systemic therapy (chemo- as well as endocrine treatments) clearly showed to significantly benefit in terms of disease-free and overall survival. This evolution has been extensively expounded on by the Worldwide Oxford Overview and the Expert Consensus Panel at the fourth International Conference ‘on Adjuvant Therapy of Primary Breast Cancer in St. Gallen (Early Breast Cancer Trialists‘ Collaborative Group 1992; Glick et al. 1992). What has happened since then? During the past 3-5 years | | Pindex | Conference proceedings 1996 |
The information of publication is updating
|
|
发表于 2025-3-21 17:45:41
